Unstable angina: integrating new treatments.
Although aspirin plus heparin remains the gold standard, clinicians will soon be able to select, from an array of antithrombotic strategies, the agents that best match the patient's hemodynamic status. Revascularization is not routinely indicated; it should be reserved for high-risk patients in whom medical therapy has failed, who have had a myocardial infarction, or who have other compromising factors.
Schulman
S P
SP
Johns Hopkins University School of Medicine, Baltimore, USA.
D000077284:Abciximab; D000789:Angina, Unstable / Q000175:diagnosis / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000075202:Contraindications; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D009204:Myocardial Revascularization; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment; D015912:Thrombolytic Therapy
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin; D000077284:Abciximab